11/20
11:12 am
stok
Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now [Yahoo! Finance]
Low
Report
Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now [Yahoo! Finance]
11/8
11:57 am
stok
Wall Street Analysts Believe Stoke Therapeutics (STOK) Could Rally 66.84%: Here's is How to Trade [Yahoo! Finance]
Low
Report
Wall Street Analysts Believe Stoke Therapeutics (STOK) Could Rally 66.84%: Here's is How to Trade [Yahoo! Finance]
11/6
08:07 am
stok
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
Medium
Report
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.
11/6
08:07 am
stok
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Medium
Report
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
11/6
07:21 am
stok
Need To Know: Analysts Are Much More Bullish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenues [Yahoo! Finance]
Medium
Report
Need To Know: Analysts Are Much More Bullish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenues [Yahoo! Finance]
11/5
07:00 am
stok
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
Medium
Report
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
10/15
07:50 am
stok
Stoke Therapeutics, Inc. (NASDAQ: STOK) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Low
Report
Stoke Therapeutics, Inc. (NASDAQ: STOK) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
10/14
09:02 am
stok
Stoke Therapeutics, Inc. (NASDAQ: STOK) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $18.00 price target on the stock.
Medium
Report
Stoke Therapeutics, Inc. (NASDAQ: STOK) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $18.00 price target on the stock.
9/11
08:02 am
stok
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Medium
Report
Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
9/10
07:00 am
stok
Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome
Medium
Report
Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome
9/7
04:53 am
stok
Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome [Seeking Alpha]
Medium
Report
Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome [Seeking Alpha]
9/4
08:00 am
stok
Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer
Medium
Report
Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer
9/3
08:00 am
stok
Stoke Therapeutics to Present at Upcoming Investor Conferences in September
Medium
Report
Stoke Therapeutics to Present at Upcoming Investor Conferences in September
9/3
08:00 am
stok
Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome
Medium
Report
Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome